Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Multiple Sclerosis | Research

The impact of the COVID-19 pandemic on neuropsychiatric and sleep disorders, and quality of life in individuals with neurodegenerative and demyelinating diseases: a systematic review and meta-analysis of observational studies

Authors: Marcos Paulo Braz de Oliveira, Ana Emilia Fonseca de Castro, Andressa Leticia Miri, Carla Rigo Lima, Brendon David Truax, Vanessa Suziane Probst, Suhaila Mahmoud Smaili

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

The coronavirus disease 2019 (COVID-19) pandemic has affected the mental health, sleep and quality of life, especially in individuals with chronic disease. Therefore, the purpose of this systematic review and meta-analysis was to investigate the impact of the COVID-19 pandemic on neuropsychiatric disorders (depression, anxiety, stress), sleep disorders (sleep quality, insomnia) and quality of life in individuals with Parkinson’s disease (PD), Multiple Sclerosis (MS) and Alzheimer's disease (AD) compared to healthy controls.

Methods

Seven databases (Medline, Embase, ScienceDirect, Web of Science, The Cochrane Library, Scielo and Lilacs) were searched between March 2020 and December 2022. Observational studies (i.e., cross-sectional, case–control, cohort) were included. GRADE approach was used to assess the quality of evidence and strength of the recommendation. Effect size was calculated using standardized mean differences (SMD; random effects model). A customized Downs and Black checklist was used to assess the risk of bias.

Results

Eighteen studies (PD = 7, MS = 11) were included. A total of 627 individuals with PD (healthy controls = 857) and 3923 individuals with MS (healthy controls = 2432) were analyzed. Twelve studies (PD = 4, MS = 8) were included in the meta-analysis. Individuals with PD had significantly elevated levels of depression (very low evidence, SMD = 0.40, p = 0.04) and stress (very low evidence, SMD = 0.60, p < 0.0001). There was no difference in anxiety (p = 0.08). Individuals with MS had significantly higher levels of depression (very low evidence, SMD = 0.73, p = 0.007) and stress (low evidence, SMD = 0.69, p = 0.03) and low quality of life (very low evidence, SMD = 0.77, p = 0.006). There was no difference in anxiety (p = 0.05) and sleep quality (p = 0.13). It was not possible to synthesize evidence in individuals with AD and sleep disorder (insomnia).

Conclusion

In general, the COVID-19 pandemic negatively impacted individuals with PD and MS. Individuals with PD showed significantly higher levels of depression and stress; and individuals with MS presented significantly higher depression and stress levels, as well as significantly lower quality of life when compared to healthy controls. Further studies are needed to investigate the impact of the COVID-19 pandemic in individuals with AD.
Literature
1.
2.
3.
Geng JS, Yu XL, Bao HN, et al. Chronic diseases as a predictor for severity and mortality of COVID-19: a systematic review with cumulative meta-analysis. Front Med (Lausanne). 2021;8: 588013.PubMedCrossRef
4.
Pathak N, Vimal SK, Tandon I, Agrawal L, Hongyi C, Bhattacharyya S. Neurodegenerative disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: an early diagnostic approach for precision treatment. Metab Brain Dis. 2022;37:67–104.PubMedCrossRef
5.
Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10: a033118.PubMedPubMedCentralCrossRef
6.
Kouli A, Torsney KM, Kuan WL. Parkinson’s disease: etiology, neuropathology, and pathogenesis. In: Kouli A, Torsney KM, Kuan WK, Stoker TB, Greenland JC, editors. Parkinson’s disease: pathogenesis and clinical aspects. Brisbane: Codon Publications; 2018. p. 3–26.CrossRef
7.
8.
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541–54.PubMedPubMedCentralCrossRef
9.
Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. 2021;268:409–19.PubMedCrossRef
10.
Cummings JL, Diaz C, Levy M, Binetti G, I Litvan I. Neuropsychiatric syndromes in neurodegenerative disease: frequency and signficance. Semin Clin Neuropsychiatry. 1996;1:241–47.
11.
Welsh MD. Measurement of quality of life in neurodegenerative disorders. Curr Neurol Neurosci Rep. 2001;1:346–9.PubMedCrossRef
12.
13.
Iodice F, Cassano V, Rossini PM. Direct and indirect neurological, cognitive, and behavioral effects of COVID-19 on the healthy elderly, mild-cognitive-impairment, and Alzheimer’s disease populations. Neurol Sci. 2021;42:455–65.PubMedPubMedCentralCrossRef
14.
Brooks SK, Weston D, Greenberg N. Social and psychological impact of the COVID-19 pandemic on people with Parkinson’s disease: a scoping review. Public Health. 2021;199:77–86.PubMedCrossRef
15.
Abasiyanik Z, Kurt M, Kahraman T. COVID-19 and physical activity behaviour in people with neurological diseases: a systematic review. J Dev Phys Disabil. 2022;34:987–1012.PubMedPubMedCentralCrossRef
16.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.PubMedCrossRef
17.
Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley and Sons; 2019.CrossRef
18.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.PubMedPubMedCentralCrossRef
19.
Nobre MR, Bernardo WM, Jatene FB. Evidence based clinical practice. part 1 - well structured clinical questions. Rev Assoc Med Bras. 2003;49:445–9.PubMedCrossRef
20.
Bernardo WM, Nobre MR, Jatene FB. Evidence-based clinical practice. part II– searching evidence databases. Rev Assoc Med Bras. 2004;50:104–8.PubMedCrossRef
21.
Hernandes E, Zamboni A, Fabbri S. Using GQM and TAM to evaluate StArt - a tool that supports systematic review. CLEI Electr J. 2012;15:13–25.
22.
Hedges L, Olkin I. Statistical Methods for Meta-analysis. 1st ed. New York: Academic Press; 1985.
23.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84.PubMedPubMedCentralCrossRef
24.
Zanardi APJ, Silva ES, Costa RR, et al. Gait parameters of Parkinson’s disease compared with healthy controls: a systematic review and meta-analysis. Sci Rep. 2021;11:752.PubMedPubMedCentralCrossRef
25.
Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. rating the quality of evidence - publication bias. J Clin Epidemiol. 2011;64:1277–82.PubMedCrossRef
26.
Cohen J. The concepts of power analysis. In: Cohen J, editor. Statistical power analysis for the behavioral sciences. New York: Lawrence Erlbaum Associates Inc; 1988. p. 1–17.
27.
28.
Salari M, Zali A, Ashrafi F, et al. Incidence of anxiety in Parkinson’s disease during the coronavirus disease (COVID-19) pandemic. Mov Disord. 2020;35:1095–6.PubMedPubMedCentralCrossRef
29.
Shalash A, Roushdy T, Essam M, et al. Mental health, physical activity, and quality of life in Parkinson’s disease during COVID-19 pandemic. Mov Disord. 2020;35:1097–9.PubMedPubMedCentralCrossRef
30.
Xia Y, Kou L, Zhang G, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Med. 2020;75:428–33.PubMedPubMedCentralCrossRef
31.
Balci B, Aktar B, Buran S, Tas M, Colakoglu BD. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson’s disease. Int J Rehabil Res. 2021;44:173–6.PubMedCrossRef
32.
Blakemore RL, Pascoe MJ, Horne K-L, et al. Higher perceived stress and exacerbated motor symptoms in Parkinson’s disease during the COVID-19 lockdown in New Zealand. N Z Med J. 2021;134:44–51.PubMed
33.
Kitani-Morii F, Kasai T, Horiguchi G, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS ONE. 2021;16: e0245864.PubMedPubMedCentralCrossRef
34.
Suzuki K, Numao A, Komagamine T, et al. Impact of the COVID-19 pandemic on the quality of life of patients with Parkinson’s disease and their caregivers: a single-center survey in Tochigi prefecture. J Parkinsons Dis. 2021;11:1047–56.PubMedCrossRef
35.
36.
Stojanov A, Malobabic M, Milosevic V, et al. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak. Mult Scler Relat Disord. 2020;45: 102407.PubMedPubMedCentralCrossRef
37.
Talaat E, Ramadan I, Aly S, Hamdy E. Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic? Mult Scler Relat Disord. 2020;46: 102580.PubMedPubMedCentralCrossRef
38.
Bonavita S, Sparaco M, Russo A, Borriello G, Lavorgna L. Perceived stress and social support in a large population of people with multiple sclerosis recruited online through the COVID-19 pandemic. Eur J Neurol. 2021;28:3396–402.PubMedCrossRef
39.
Costabile T, Carotenuto A, Lavorgna L, et al. COVID-19 pandemic and mental distress in multiple sclerosis: Implications for clinical management. Eur J Neurol. 2021;28:3375–83.PubMedCrossRef
40.
Garjani A, Hunter R, Law GR, et al. Mental health of people with multiple sclerosis during the COVID-19 outbreak: a prospective cohort and cross-sectional case-control study of the UK MS register. Mult Scler. 2022;28:1060–71.PubMedCrossRef
41.
Shaygannejad V, Afshari-Safavi A, Hatef B. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus. Neurol Sci. 2021;42:2891–901.PubMedCrossRef
42.
Stojanov A, Vojinovic S, Stojanov J, et al. Quality of sleep and fatigue in patients with the relapsing-remitting multiple sclerosis during the coronavirus disease-2019 pandemic. Clin Neurol Neurosurg. 2021;205: 106640.PubMedCrossRef
43.
44.
Koc ER, Demir AB, Topaloglu E, Turan OF, Ozkaya G. Effects of quarantine applied during the COVID-19 pandemic on mental health and quality of life in patients with multiple sclerosis and healthy controls. Neurol Sci. 2022;43:2263–69.
45.
46.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.PubMedPubMedCentralCrossRef
47.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.PubMedCrossRef
48.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.PubMedCrossRef
49.
Chen H, Zhao EJ, Zhang W, et al. Meta-analyses on prevalence of selected Parkinson’s nonmotor symptoms before and after diagnosis. Transl Neurodegener. 2015;4:1.PubMedPubMedCentralCrossRef
50.
51.
Wu PL, Lee M, Huang TT. Effectiveness of physical activity on patients with depression and Parkinson’s disease: a systematic review. PLoS ONE. 2017;12: e0181515.PubMedPubMedCentralCrossRef
52.
Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson’s disease. Exp Neurol. 2012;233:79–86.PubMedCrossRef
53.
54.
Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41.PubMedCrossRef
55.
Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26.PubMedCrossRef
56.
Lee SA. Coronavirus anxiety scale: a brief mental health screener for COVID-19 related anxiety. Death Stud. 2020;44:393–401.PubMedCrossRef
57.
Briones-Buixassa L, Milà R, Aragonès JM, Bufill E, Olaya B, Arrufat FX. Stress and multiple sclerosis: a systematic review considering potential moderating and mediating factors and methods of assessing stress. Health Psychol Open. 2015;2:2055102915612271.PubMedPubMedCentralCrossRef
58.
Artemiadis AK, Vervainioti AA, Alexopoulos EC, Rombos A, Anagnostouli MC, Darviri C. Stress management and multiple sclerosis: a randomized controlled trial. Arch Clin Neuropsychol. 2012;27:406–16.PubMedCrossRef
59.
Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler. 2015;21:342–9.PubMedPubMedCentralCrossRef
60.
61.
Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912–20.PubMedPubMedCentralCrossRef
62.
Gil-González I, Martín-Rodríguez A, Conrad R, Pérez-San-Gregorio MA. Quality of life in adults with multiple sclerosis: a systematic review. BMJ Open. 2020;10: e041249.PubMedPubMedCentralCrossRef
63.
Hughes MC, Liu Y, Baumbach A. Impact of COVID-19 on the health and well-being of informal caregivers of people with dementia: a rapid systematic review. Gerontol Geriatr Med. 2021;7:23337214211020164.PubMedPubMedCentralCrossRef
64.
Simonetti A, Pais C, Jones M, et al. Neuropsychiatric symptoms in elderly with dementia during COVID-19 pandemic: definition, treatment, and future directions. Front Psychiatry. 2020;11: 579842.PubMedPubMedCentralCrossRef
65.
Metadata
Title
The impact of the COVID-19 pandemic on neuropsychiatric and sleep disorders, and quality of life in individuals with neurodegenerative and demyelinating diseases: a systematic review and meta-analysis of observational studies
Authors
Marcos Paulo Braz de Oliveira
Ana Emilia Fonseca de Castro
Andressa Leticia Miri
Carla Rigo Lima
Brendon David Truax
Vanessa Suziane Probst
Suhaila Mahmoud Smaili
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03176-9

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Research article

Computed tomography derived cervical fat-free muscle fraction as an imaging-based outcome marker in patients with acute ischemic stroke: a pilot study

Case report

Anisocoria without extraocular muscle impairment due to moderate traumatic brain injury with midbrain contusion: a case report

Case Report

Ischaemic stroke with multi-focal venous and arterial thrombosis due to hyperhomocysteinemia: anabolic androgenic steroid use and MTHFR c.667 C > T variant – a case report

Study Protocol

Directional versus ring-mode deep brain stimulation for Parkinson’s disease: protocol of a multi-centre double-blind randomised crossover trial

Research

Is coronary artery calcium an independent risk factor for white matter hyperintensity?

Research

Clinical prediction score for prolonged length of hospital stay in aneurysmal subarachnoid hemorrhage